Hamamoto Ryuji, Komatsu Masaaki, Yamada Masayoshi, Kobayashi Kazuma, Takahashi Masamichi, Miyake Mototaka, Jinnai Shunichi, Koyama Takafumi, Kouno Nobuji, Machino Hidenori, Takahashi Satoshi, Asada Ken, Ueda Naonori, Kaneko Syuzo
Division of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, Japan.
Cancer Translational Research Team, RIKEN Center for Advanced Intelligence Project, Tokyo, Japan.
Cancer Sci. 2025 Feb;116(2):297-307. doi: 10.1111/cas.16395. Epub 2024 Nov 18.
The expectations for artificial intelligence (AI) technology have increased considerably in recent years, mainly due to the emergence of deep learning. At present, AI technology is being used for various purposes and has brought about change in society. In particular, the rapid development of generative AI technology, exemplified by ChatGPT, has amplified the societal impact of AI. The medical field is no exception, with a wide range of AI technologies being introduced for basic and applied research. Further, AI-equipped software as a medical device (AI-SaMD) is also being approved by regulatory bodies. Combined with the advent of big data, data-driven research utilizing AI is actively pursued. Nevertheless, while AI technology has great potential, it also presents many challenges that require careful consideration. In this review, we introduce the current status of AI-based cancer research, especially from the perspective of clinical application, and discuss the associated challenges and future directions, with the aim of helping to promote cancer research that utilizes effective AI technology.
近年来,人们对人工智能(AI)技术的期望大幅提高,这主要归功于深度学习的出现。目前,AI技术正被用于各种目的,并给社会带来了变革。特别是以ChatGPT为代表的生成式AI技术的迅速发展,扩大了AI对社会的影响。医学领域也不例外,各种各样的AI技术被引入基础研究和应用研究。此外,作为医疗设备的AI软件(AI-SaMD)也正在获得监管机构的批准。随着大数据时代的到来,利用AI进行数据驱动的研究也在积极开展。然而,尽管AI技术具有巨大潜力,但它也带来了许多需要仔细考虑的挑战。在这篇综述中,我们介绍了基于AI的癌症研究的现状,特别是从临床应用的角度,并讨论了相关挑战和未来方向,旨在推动利用有效AI技术的癌症研究。